Barclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang — Canaccord Cuts Progyny (PGNY) on Cautious 2026 Outlook
Two healthcare names are drawing fresh analyst attention this week as Wall Street recalibrates around a landmark GLP-1 truce and a fertility benefits company navigating a murky 2026 outlook. Barclays analyst Glen…